Industry Liaison Forum
The IAS-ILF is a mechanism to inform and support collaboration and partnership between industry, the IAS and other stakeholders. It performs this broad task by providing opportunities for industry to understand the IAS’s values, interests and priorities, and vice versa, seeking common ground to enhance the impact of the global response to HIV and related comorbidities.
The IAS-ILF aims to promote constructive interactions among all stakeholders, including industry, and convene experts from industry and non-industry organizations to discuss topics relevant to IAS Member Priorities. The IAS-ILF is designed to take advantage of the IAS’s key strengths: its well-respected convening power; its acknowledged independence towards industry and other key partners and stakeholders; and its diverse working groups composed of some of the world’s top thought leaders and scientific experts in a wide array of fields.
IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV
Removing barriers and seizing opportunities in paediatric HIV
Following the success of the IAS-ILF Industry Roundtable on Paediatric Antiretrovirals, held in Geneva, Switzerland, in November 2013, the IAS-ILF and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) teamed up to organize a follow-up roundtable on paediatric HIV. This closed meeting was held in conjunction with AIDS 2014 (20-25 July 2014, Melbourne, Australia). It was aimed at bringing cohorts (through the CIPHER Cohort Collaboration) and industry together for an informal discussion and knowledge sharing between stakeholders, hoping to extend collaboration between cohort investigators and industry. Normative and regulatory agencies were also represented. The IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV was co-chaired by Lynne Mofenson (US National Institutes of Health, USA) and Shaffiq Essajee (Clinton Health Access Initiative, USA). This thematic roundtable highlighted the common goal shared by stakeholders: contributing to the development and distribution of better antiretroviral regimens to more infants, children and adolescents. Challenges and opportunities were highlighted during the discussion, as well as potential avenues for follow up through the CIPHER Cohort Collaboration.
The meeting agenda, report and presentations are available for download here.